BioStem Technologies Announces It Received Nasdaq Approval For The Company’s Common Stock For Listing On The Nasdaq Capital Market; Co. To Begin Trading On Nasdaq On August 7, 2026 Under The Ticker Symbol "BSEM"
BioStem Technologies Inc. (OTC:BSEM) ("BioStem" or the "Company"), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft
BioStem Technologies got permission to move its stock from a smaller market to Nasdaq, a bigger and more famous stock market, starting August 7, 2026. When a company moves to a bigger market, it usually means people can trade it more easily and the company might be growing, so watch if the stock stays healthy and if the company keeps its promises.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.